RespireRx Pharmaceuticals Inc (RSPI)

[neuroinv]

I don't recall what the final unit price I used was (I did that estimate at least 9 or 10 months ago). It was probably in the $500 range--multiplied by a calculation of the number of crash carts in ERs, inpatient units, outpatient surgical centers. That would be the IV 'rescue' formulation. I would expect JCAH regs would require replacement of the crash cart contents every year, though if there is a pharmacist who reads the board, they'd have a better idea how long the shelf-life of this kind of compound is.I think that hospitals/surgical centers would consider this a reasonable cost for reducing liability exposure.

This is very different from the pricing for preventative use, which would be oral, and given pre-surgery. That would have to be priced low enough that it could be included in the anesthesiology fee bundle third party payors would accept, perhaps increased slightly. There volume would be the key.

In any event, my estimate of $700-800 million is lower than Cortex's market research consultant came up with, which was slightly over a billion dollars annually. I do not know what their unit cost estimates were.

NeuroInvestment